Journal of Cardiac Failure

• 

  Publication Venue For

  • Using Data to Facilitate Peer Reviewer Engagement - A JCF Update.  29:717-718. 2023
  • Why do exercise hemodynamics matter?.  S1071-9164(23)00155-0. 2023
  • Inconsistent Outcome Reporting in Heart Failure Randomized Controlled Trials..  29:425-433. 2023
  • Lifting and Healing as We Climb: Women's Heart Month..  29:121-123. 2023
  • Increased Opportunities for Transplantation for Women in the New Heart Allocation System..  28:1149-1157. 2022
  • The Impact of Depression on Outcomes in Patients With Heart Failure and Reduced Ejection Fraction Treated in the GUIDE-IT Trial..  27:1359-1366. 2021
  • Universal Definition and Classification of Heart Failure: Pharmacists' Perspective: Optimizing Guideline-Directed Medical Therapy and Educating Stakeholders..  27:1310-1312. 2021
  • Hepatocyte Growth Factor and Incident Heart Failure Subtypes: The Multi-Ethnic Study of Atherosclerosis (MESA)..  27:981-990. 2021
  • Impact of a Formal Advance Care Planning Program on End-of-Life Care for Patients With Heart Failure: Results From a Randomized Controlled Trial..  26:594-598. 2020
  • Impact of Obesity on Ventricular Assist Device Outcomes..  26:287-297. 2020
  • High Transpulmonary Artery Gradient Obtained at the Time of Left Ventricular Assist Device Implantation Negatively Affects Survival After Cardiac Transplantation.  25:777-784. 2019
  • A Prospective Pilot Study of Pocket-Carried Ultrasound Pre- and Postdischarge Inferior Vena Cava Assessment for Prediction of Heart Failure Rehospitalization..  24:614-617. 2018
  • Prognostic Impact of Pulmonary Artery Pulsatility Index (PAPi) in Patients With Advanced Heart Failure: Insights From the ESCAPE Trial..  24:453-459. 2018
  • HFSA President's Paper 2017
  • Palliative Care in Heart Failure: Results of a Randomized, Controlled Clinical Trial.  22:940-940. 2016
  • Liver Function, In-Hospital, and Post-Discharge Clinical Outcome in Patients With Acute Heart Failure-Results From the Relaxin for the Treatment of Patients With Acute Heart Failure Study 2014
  • A trial of family partnership and education interventions in heart failure.  19:829-841. 2013
  • A trial of family partnership and education interventions in heart failure.  19:829-841. 2013
  • Percutaneous Hemodynamic Support (Impella) in Patients With Advanced Heart Failure and/or Cardiogenic Shock Not Eligible to PROTECT II Trial.  18:S101-S101. 2012
  • Erratum: Flexible diuretic titration in chronic heart failure: Where is the evidence? (Journal of Cardiac Failure (2011) 17 (944-954)).  18:172. 2012
  • Flexible Diuretic Titration in Chronic Heart Failure: Where Is the Evidence? (vol 17, pg 944, 2011).  18:172-172. 2012
  • Association between VE-VCO2 Slope and Resting Hemodynamic Measurements in Ambulatory Heart Failure (HF) Patients: An Analysis from the Duke Advanced HF Database.  17:S8-S9. 2011
  • Cystatin C as a Biomarker of Worsening Renal Function in Acute Heart Failure: Insights from the DOSE Study.  17:S58-S58. 2011
  • International Variation in Use of Anticoagulation among Heart Failure Patients with Atrial Fibrillation.  17:S72-S72. 2011
  • Plasma Renin Activity (PRA) Predicts Diuretic Resistance in Acute Heart Failure Patients: An Ancillary Study of the Diuretic Optimization Strategies Evaluation in Acute Heart Failure (DOSE-AHF).  17:S25-S26. 2011
  • Regadenoson Stress SPECT MPI for Prediction of Outcomes in Patients with Impaired Left Ventricular Function: A Comparison with Adenosine Stress.  17:S78-S79. 2011
  • Resource Use and Medical Costs by Cause of Death in HF-ACTION.  17:S78-S78. 2011
  • Seattle Heart Failure Model Scores Significantly Predict Medical Resource Use and Costs in HF-ACTION.  17:S80-S80. 2011
  • Ultrafiltration is Associated with Worsening Renal Function, and Electrolyte Abnormalities in Patients with Diuretic Refractory Heart Failure and Renal Dysfunction.  17:S96-S96. 2011
  • Highlights of the 2009 Scientific Sessions of the Heart Failure Society of America, Boston, MA, September 13-16, 2009.  16:2-8. 2010
  • Relationship of Baseline Gated Rest SPECT Myocardial Perfusion Imaging to Death and Hospitalization in Heart Failure Patients: Results from the Nuclear Substudy of the HF-ACTION Trial.  15:814-814. 2009
  • Changes in Dyspnea during Treatment of Acute Heart Failure Are Correlated with Clinical Signs, Rehospitalizations and Mortality. Results from the Pre-RELAX-AHF Trial.  15:S62-S63. 2009
  • Cost of Exercise Training and Its Impact on Medical Resource Use and Costs: Results of HF-ACTION.  15:S93-S93. 2009
  • Effect of Cardiac Rehabilitation Visits on Mortality among Elderly Medicare Beneficiaries with Heart Failure.  15:S99-S99. 2009
  • Effects of Successful Depression Intervention on Health Status in Patients with Chronic Heart Failure and Major Depressive Disorder: Findings from the SADHART-CHF Randomized Controlled Trial.  15:S86-S86. 2009
  • Marital Status and Prognosis of Patients with Heart Failure.  15:S91-S91. 2009
  • Time to Treatment and Vasodilator Efficacy in Acute Heart Failure: Results from the Pre-RELAX-AHF Study.  15:S68-S68. 2009
  • Vasodilators in Acute Heart Failure (AHF): Does Blood Pressure Matter? Results from Pre-Relax-AHF.  15:S74-S74. 2009
  • Worsening Renal Function in Acute Heart Failure: Change in Blood Pressure and Effects of Relaxin.  15:S63-S63. 2009
  • Diastolic Dysfunction (DD) Is a Useful Marker to Risk Stratify Patients with Frequent COPD Exacerbations and Normal Left Ventricular Ejection Fraction (LVEF).  14:S86-S86. 2008
  • Overview of Acute Decompensated Heart Failure in Argentina: Lessons Learned from Five Registries during the Last Decade.  11:S186-S186. 2005
  • Randomized trial of a nurse-administered, telephone-based disease management program for patients with heart failure..  11:358-365. 2005
  • Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST)..  11:260-269. 2005
  • Demographics, clinical characteristics, and outcomes of patients hospitalized for decompensated heart failure: observations from the IMPACT-HF registry..  11:200-205. 2005
  • Risk stratification after hospitalization for decompensated heart failure..  10:460-466. 2004
  • The impact of arrhythmias in acute heart failure..  10:279-284. 2004
  • Why is depression bad for the failing heart? A review of the mechanistic relationship between depression and heart failure..  10:258-271. 2004
  • The Warfarin and Antiplatelet Therapy in Heart Failure trial (WATCH): rationale, design, and baseline patient characteristics..  10:101-112. 2004
  • Therapeutic exercise for individuals with heart failure: special attention to older women with heart failure..  10:165-173. 2004
  • Relation of serum levels of mast cell tryptase of left ventricular systolic function, left ventricular volume or congestive heart failure..  10:31-35. 2004
  • Quality still doesn't pay in heart failure management..  9:263-265. 2003
  • Cardiac hypertrophy: role of G protein-coupled receptors..  8:S409-S414. 2002
  • Plasma matrix metalloproteinase and inhibitor profiles in patients with heart failure..  8:390-398. 2002
  • The prognostic importance of different definitions of worsening renal function in congestive heart failure..  8:136-141. 2002
  • Hemodynamic profiles of advanced heart failure: association with clinical characteristics and long-term outcomes..  7:105-113. 2001
  • Long-acting natriuretic peptide, vessel dilator, and kaliuretic peptide enhance urinary excretion rate of albumin, total protein, and beta(2)-microglobulin in patients with congestive heart failure..  7:55-63. 2001
  • Rationale and design of a randomized clinical trial to assess the safety and efficacy of cardiac resynchronization therapy in patients with advanced heart failure: the Multicenter InSync Randomized Clinical Evaluation (MIRACLE)..  6:369-380. 2000
  • Candesartan in heart failure--assessment of reduction in mortality and morbidity (CHARM): rationale and design. Charm-Programme Investigators..  5:276-282. 1999
  • Angiotensin II blockade followed by growth hormone as adjunctive therapy after experimental myocardial infarction..  4:213-224. 1998
  • Regional differences in the characteristics and treatment of patients participating in an international heart failure trial. The Assessment of Treatment with Lisinopril and Survival (ATLAS) Trial Investigators..  4:3-8. 1998
  • Erratum: Regional differences in the characteristics and treatment of patients participating in an international heart failure trial (Journal of Cardiac Failure (1998) 4:3)).  4:153. 1998
  • Force-frequency relations in the failing rabbit heart and responses to adrenergic stimulation..  3:27-39. 1997
  • Biatrial appendage hypertrophy but not ventricular hypertrophy: a unique feature of canine pacing-induced heart failure..  2:127-132. 1996
  • How does intermittent pacing modify the response to rapid ventricular pacing in experimental heart failure?.  1:223-228. 1995
  • Rethinking Rehospitalization in Heart Failure Care Transitions: Heterogeneity in Use Typologies. 2023
  • Angiopoetin 2 Predicts Clinical Outcomes And Recovery Of Ventricular Function In Heart Failure 2022
  • Echocardiographic Variables Predict Outcome In Children, Adolescents, And Adults With Barth Syndrome: A Longitudinal Observational Study 2022
  • Performance On Guideline Directed Medical Therapy Remains Low In A Cluster-randomized Trial: Results From CONNECT-HF 2022
  • Rehabilitation Therapy In Older Patients Hospitalized With Acute Heart Failure And Comorbid Diabetes: Insights From Rehab-hf 2022
  • Contemporary Use of Venoarterial Extracorporeal Membrane Oxygenation: Insights from the Multicenter RESCUE Registry 2021
  • Assessing for a Differential Treatment Effect with Nesiritide by Body Mass Index 2020
  • Atrial Natriuretic Peptide Mediates Reverse Cardiac Remodeling During Treatment with Sacubitril/Valsartan in Patients with Heart Failure with Reduced Ejection Fraction 2020
  • Changes in Care Delivery for Patients with Heart Failure During the Covid-19 Pandemic: Results of a Multicenter Survey 2020
  • Circulating Protein Biomarkers Associated with Heart Failure with Preserved Ejection Fraction 2020
  • Clinical Impact of A Newly Established Heart Failure Practice on 30-day Readmissions 2020
  • Effect Of Vericiguat In Victoria According To Guideline-directed Medical Therapy 2020
  • Effect of Vericiguat in Victoria According to Guideline-directed Medical Therapy 2020
  • Efficacy And Safety of Low-dose Intravenous Vitamin K For International Normalized Ratio Reversal In Left Ventricular Assist Device Patients 2020
  • Nitrate Use And Changes In Functional Status In Black Patients With Chronic Heart Failure With Reduced Ejection Fraction: Insights From The HFACTION Trial 2020
  • Non-participation in a Heart Failure Clinical Trial: Perspectives and Opportunities from the VICTORIA Trial and Simultaneous Registry 2020
  • Racial and Ethnic Differences in Biomarkers, Health Status, and Cardiac Remodeling in Patients with Heart Failure with Reduced Ejection Fraction Treated with Sacubitril/valsartan 2020
  • Sacubitril/valsartan Initiation and Adherence Patterns Following Hospitalization for Heart Failure 2020
  • Sex-based Differences in Biomarkers, Quality of Life, and Reverse Cardiac Remodeling in Patients with Heart Failure with Reduced Ejection Fraction Treated with Sacubitril/valsartan 2020
  • Torsemide Is Associated with Higher Levels of Urinary Biomarkers of Tubular Injury Compared to Furosemide 2020
  • Clinical Effectiveness of Sacubitril/valsartan among Patients Hospitalized for Heart Failure with Reduced Ejection Fraction 2019
  • Effects of Angiotensin Receptor/Neprilysin Inhibitor Therapy on Amino-terminal Pro-B-Type Natriuretic Peptide and Cardiac Remodeling in Heart Failure with Reduced Ejection Fraction: The PROVE-HF Study 2019
  • Anticipated vs. Actual Outcomes of Elective Inotrope Initiation in Hemodynamically Stable Heart Failure Patients 2019
  • Association between Left Ventricular Ejection Fraction and Worsening Renal Function in Acute Heart Failure: Insights from the RELAX-AHF-2 Trial 2019
  • Association of Atrial Fibrillation and Postoperative Right Ventricular Failure after Left Ventricular Assist Device Implantation: Systematic Review and Meta-Analysis 2019
  • Barriers to Clinical Trial Efficiency: The Heart Failure Collaboratory Industry Experience 2019
  • Differences between Academic and Non-Academic Institutions in Heart Failure Clinical Trials in North America: Insights from the HFSA Research Network Survey 2019
  • Guideline Directed Medical Therapy in Heart Failure Trials: A New Proposed Scoring System 2019
  • Increased eGFR Variability is Observed in Patients with HFrEF Compared to no HF or HFpEF in the Setting of Chronic Kidney Disease 2019
  • Optimal Medical Therapy in Heart Failure: Reasons for Lack of Medication Titration in the GUIDE IT Trial 2019
  • Patients Accept Mortality Risk for Improvements in Physical Functioning in Secondary Mitral Regurgitation 2019
  • Patterns of Change in Quality of Life with a Palliative Care Intervention for Patients with Advanced Heart Failure: Insights from PAL-HF 2019
  • Problem of 30-Day Readmission for Heart Failure Could Be Improved. Results of IMPEDANCE-HF Extended Trial 2019
  • Representativeness of the PIONEER-HF Clinical Trial Population in Patients Hospitalized with Heart Failure 2019
  • Residual Congestion on Discharge for Heart Failure Assessed by Impedance Technique Predicts 30-Day and One-Year Heart Failure Death. Results of IMPEDANCE-HF Extended Trial 2019
  • Subcutaneous Furosemide in the Treatment of Patients with Decompensated Heart Failure: Data from the Sub-Q Pilot Studies 2019
  • The Relationship between LVEF and Cardiovascular Outcomes Following Hospitalization for Heart failure: Insights from the RELAX-AHF-2 Trial 2019
  • Association between Age and Early Mortality Risk after Implantable Cardioverter Defibrillator Implantation within The Veteran Affairs Health System 2018
  • Association between Sacubitril/Valsartan Initiation and Health Status Outcomes inHeart Failure with Reduced Ejection Fraction:Findings from the CHAMP-HF Registry 2018
  • Causes of Death Among Patients with and without DIabetes and Chronic Heart Failure: Insights from the HF-ACTION and ASIAN-HF Registry 2018
  • Diabetes is Associated with Worse In-Hospital and 30-Day Post-Discharge Morbidity in Patients with Heart Failure with Preserved Ejection Fraction: Findings from the Get With The Guidelines Heart Failure Registry 2018
  • Enrollment of Older Patients, Women, and Racial and Ethnic Minorities in Contemporary Heart Failure Clinical Trials 2018
  • Heart Failure Society of America Research Network Survey 2018
  • Improvements in Health Status Associated with Medication Adjustments in Outpatients with HFrEF: Insights from the CHAMP-HF Registry 2018
  • Patient and Practice Characteristics Associated with Sacubitril/Valsartan Use in the United States 2018
  • Periprocedural Risk and Survival after ICD Placement in Patients with Advanced Heart Failure 2018
  • Right Atrial Speckle Tracking Strain Echocardiography in HeartFailure 2018
  • Safety and Utility of Cardiopulmonary Exercise Testing in Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia 2018
  • The Renal Effects of Aggressive Volume Removal in Heart Failure Patients with Preexisting Worsening Renal Function 2018
  • Trends in Comorbidities and 1-Year Mortality after Implantable Cardioverter Defibrillator Implantation Within The Veteran Affairs Health System 2018
  • Use of Target Doses of Guideline Directed Medical Therapy in Heart Failure by Systolic Blood Pressure: Insights from the CHAMP-HF Registry 2018
  • Effect of Natriuretic Peptide-Guided Therapy on Outcomes in High-Risk Patients with Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial 2017
  • Effect of Omecamtiv Mecarbil in Patients with Ischemic and Non-Ischemic Heart Failure with Reduced Ejection Fraction: Results From COSMIC-HF 2017
  • Electrolyte Derangements in Heart Failure 2017
  • Loop Diuretic Change in Patients with Chronic Heart Failure: Insights From HF-ACTION 2017
  • The Burden of Non-Cardiac Comorbidities in Acute Heart Failure: Insights From ASCEND-HF 2017
  • The Prognostic Value of Diastolic and Systolic Mechanical Left Ventricular Dyssynchrony among Patients with Coronary Artery Disease and Heart Failure 2017
  • Trends and Outcomes of Cardiac Transplantation From Donors Dying of Drug Intoxication 2017
  • The Targeting Acute Congestion with Tolvaptan in Congestive Heart Failure Study: A Randomized, Double blind, Placebo-Controlled Trial in Acute Heart Failure 2016
  • Development of a Symptom Tracker for Use by Patients With Heart Failure 2016
  • Exercise Training in Patients with Chronic Heart Failure and Atrial Fibrillation: Results from the HF-ACTION Trial 2016
  • Extra-Cardiac Disease Burden Contributes More Than Cardiac Disease Burden to Risk of Cardiovascular Outcomes in Patient with Preserved Ejection Fraction 2016
  • Improved Contractility and Evolution of Ventricular Remodelling Through Time in the Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF 2016
  • Laboratory Monitoring after Inpatient and Outpatient Initiation of Mineralocorticoid Receptor Antagonist Therapy in Patients with Heart Failure 2016
  • Regional Differences during Acute Heart Failure Hospitalizations of Patients with Heart Failure with Preserved Ejection Fraction: Insights From ASCEND-HF 2016
  • The Effect of Omecamtiv Mecarbil on Symptoms of Heart Failure in the Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF) 2016
  • CUPID 2: A Phase 2b Trial Investigating the Efficacy and Safety of the Intracoronary Administration of AAV1/SERCA2a in Patients with Advanced Heart Failure 2015
  • Elevated Heart Rate in Patients with Heart Failure with Reduced Ejection Fraction: Associations with One-Year Survival and Costs 2015
  • Elevated Total Bilirubin on Admission is a Marker of Worse 30- and 180-Day Outcomes for Patients With Acute HF: Insights From ASCEND-HF 2015
  • Lack of Improvement in 30-day Readmission Rates for Patients Hospitalized with Heart Failure: Data from Get With The Guidelines-Heart Failure Registry 2015
  • Long Term Support of Acute, Refractory Cardiogenic Shock with an Extracorporeal, Continuous Flow Ventricular Assist Device: A Seven Year Experience 2015
  • Novel Protein Glycan Inflammatory Biomarkers Predict Adverse Events in Heart Failure with Preserved Ejection Fraction 2015
  • Prediction of Post-Discharge Outcomes for Patients Hospitalized with Heart Failure: Results from PROTECT 2015
  • The Clinical Implications of Cardiac Troponin I Measured by an “Ultrasensitive” Assay in Acute Decompensated Heart Failure: Insights from ASCEND-HF 2015
  • Trends in the Use of Guideline-based Therapies Among Dialysis Patients Hospitalized with Heart Failure: Findings from Get With The Guidelines-Heart Failure 2015
  • A Stepwise Pharmacological Care Algorithm for Cardiorenal Syndrome for Acute Heart Failure: Insights from DOSE-AHF, CARRESS-HF, and ROSE-AHF 2014
  • Clinical Characteristics and Long Term Outcomes in Septuagenarians Undergoing Cardiac Transplantation 2014
  • Differential Response to Low Dose Dopamine or Nesiritide in Patients with Acute Heart Failure and Renal Dysfunction in Accordance to LV EF: Sub-Group Analysis of the ROSE AHF Trial 2014
  • Hemodynamic Response to Continuous Outpatient Milrinone Infusion in Advanced Heart Failure Patients with Mixed Pulmonary Hypertension 2014
  • Influence of Diuretic Dose and Route of Administration on Loop Diuretic Efficiency: Insights from the Diuretic Optimization Strategies Evaluation in Acute Heart Failure (DOSE-AHF) Trial 2014
  • Torsemide vs. Furosemide in Heart Failure Patients: Insights from Duke University Hospital 2014
  • Transient and Persistent Worsening Renal Function during Acute Heart Failure Hospitalization: Insights from the ADHERE Registry Linked to Medicare Claims 2014
  • Comparable Clinical Benefits with Beta-Blockers in Heart Failure Patients from North America and Europe: Evidence from a Meta-Analysis of Randomized Clinical Trials 2013
  • Generalizability of RELAX-AHF Clinical Trial Patients to a Large US Registry 2013
  • Nesiritide Administration in Patients Hospitalized for Acute Decompensated Heart Failure: Does Timing Matter? 2013
  • Admission Heart Rate and In-Hospital Outcomes in Patients Hospitalized for Heart Failure in Sinus Rhythm and Atrial Fibrillation 2012
  • Age, Clinical Characteristics and Outcomes of Patients With Acute Decompensated Heart Failure: Insights from the PROTECT Trial 2012
  • Beta-Blocker Selectivity in Heart Failure (HF) Patients With Chronic Obstructive Pulmonary Disease (COPD): Insights from HF-A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) 2012
  • Do BNP Levels and Prognostic Value Vary by Race/Ethnicity in Patients Hospitalized With Heart Failure? 2012
  • Early International Normalized Ratio (INR) Monitoring and Long-Term Clinical Outcomes in Warfarin Users with Heart Failure: Findings from ADHERE Linked with Medicare Claims 2012
  • Elderly Hospitalized Heart Failure Patients Have Profound Impairments in Physical Function 2012
  • Prognostic Impact of an Ischemic Etiology of Chronic Heart Failure across the Spectrum of Ejection Fractions in the CHARM Program 2012
  • Seattle Heart Failure Model Scores are Significantly Predictive of Health Utilities and Their Change Over Time 2012
  • Clinical Characteristics and Outcomes for Hospitalized Heart Failure (HF) Patients with Chronic Obstructive Pulmonary Disease (COPD): Findings from OPTIMIZE-HF 2011
  • Clinical Characteristics and Outcomes of Patients with Ischemic Cardiomyopathy (ICM) and Angina: Findings from the Duke Cardiovascular Database 2011
  • International Differences in Acute Heart Failure (AHF) Patients: Insight from the PROTECT Trial 2011
  • The PROTECT In-Hospital Risk Model: 7-Day Outcome in Patients Hospitalized with Acute Heart Failure (AHF) and Renal Dysfunction 2011
  • Admission, Discharge, or Change in BNP and Long-Term Mortality: Data from OPTIMIZE-HF Linked with Medicare Claims 2010
  • Association of Serum Bilirubin with Heart Failure Events but Not Coronary Events in Patients with Left Ventricular Systolic Dysfunction: Data from the Beta-Blocker Evaluation of Survival Trial (BEST) 2010
  • Characterization of Heart Failure Patients With Preserved Systolic Function: A Comparison between ADHERE-US Registry and ADHERE-International Registry 2010
  • Revascularization Leads to Greater Reduction in Ischemia Than Medical Therapy in Patients With Left Ventricular Dysfunction and Stable Coronary Artery Disease 2010
  • The Association of Do-Not-Resuscitate Preference With Quality of Life Preference and Mortality in Patients in the ESCAPE Trial 2010
  • Use and Predictors of Heart Failure Disease Management Referral in Patients Hospitalized With Heart Failure: Insights from the American Heart Association – Get with the Guidelines Program 2010
  • Venous Thromboembolism Prophylaxis among Elderly Heart Failure Patients and 60-Day Outcomes: An Analysis from ADHERE Linked to Medicare Claims 2010
  • Baseline Characteristics and Outcomes of Patients Who Do Not Desire Resuscitation: An Analysis of the ESCAPE Trial 2009
  • Bucindolol Decreases Time to First HF Hospitalization in Patients with Chronic Kidney Disease 2009
  • In Hospital Early (Within 5 Days) Worsening HF Predicts Adverse Outcome in Patients Admitted for AHF – Results from the Pre-RELAX-AHF Study 2009
  • Influence of Varying Geographic Populations on Outcomes in Large Beta-Blocker Trials in Heart Failure 2009
  • Mode of Death in Advanced Heart Failure: Impact of Race, Etiology and Hemodynamics in the ESCAPE Trial 2009
  • Changes in Intrathoracic Fluid Index predict subsequent adverse events: Results of the Multi-site Program to Access and Review Trending INformation and Evaluate CoRrelation to Symptoms in Patients with Heart Failure (PARTNERS HF) Trial 2008
  • Safety and Efficacy of Sertraline plus Nurse Facilitated Supportive Intervention (NFSI) versus Placebo plus Nurse Facilitated Supportive Intervention for Depression in Patients with CHF (SADHART-CHF) (10/6/08) 2008
  • Additive effects of beta(1) 389 Arg/Gly alpha(2c) 322-325 Wt/Del genotype combinations on adjudicated hospitalizations and death in the beta-blocker evaluation of survival trial (BEST) 2008
  • Determination of Cardiac Output by Impedance Cardiography: A Comparison with Cardiovascular Magnetic Resonance as a Gold-Standard 2008
  • Determination of Hospitalization Type by Investigator Case Report Form or Adjudication Committee in a Large Heart Failure Clinical Trial (BEST) 2008
  • Differences in Electrical and Mechanical Dyssynchrony as Quantified by Phase Analysis of Gated SPECT Imaging in Patients with Mild-Moderate Left Ventricular Dysfunction 2008
  • Different Patterns of LVEF/Remodeling and Clinical Endpoint Effects for Bucindolol in b 1 -AR 389 Arg/Gly Genotypes 2008
  • Features and Hospital Outcomes for Nonadherent Patients with Heart Failure: Findings from GWTG-HF 2008
  • Ischemic Cardiomyopathy Response to Bucindolol May Be Differentially Influenced by b 1 389 Arg/Gly and a 2c Genotypes 2008
  • Rationale and Design for a Phase II Study Evaluating the Effect of the Cardiac Myosin Activator, CK-1827452, on Cardiac Function, Hemodynamics, and Myocardial Oxygen Consumption in Patients with Heart Failure 2008
  • Weekend hospital admission for heart failure: Influence on Quality of care, length of stay, and in-hospital mortality 2008
  • Acute Heart Failure Associated with High Admission Blood Pressure – A Very Common, yet Distinct Vascular Disorder? 2006
  • Clinical Characteristics and Outcomes of Patients Supported with Left Ventricular Assist Devices: Are Bridge-to-Transplant and Destination Therapy Populations Different? 2006
  • Decreasing Hemoglobin during Follow-Up Is Associated with Declining Quality of Life in Unselected Outpatients with Heart Failure: Results from the Study of Anemia in a Heart Failure Population (STAMINA-HFP) Registry 2006
  • Do hospitals that provide heart failure patient education prior to discharge also promote continuity of care? A report from OPTIMIZE-HF 2006
  • Influence of the American Heart Association's Get With The Guidelines (GWTG) Program on the Quality of Care for Patients Hospitalized with Heart Failure 2006
  • Rapid (2 Minutes) Clinical Assessment of Respiratory Failure (Oxygen Saturation) and Circulatory Failure (Systolic Blood Pressure) – An Easy and Acurate Way To Risk Stratify Patients with Acute Heart Failure at Admission? 2006
  • Reliability of Heart Failure Patient Care: Initial Results from the American Heart Association's Get With The Guidelines (GWTG) Heart Failure Program 2006
  • Risk Score To Predict Survival to Hospital Discharge after Left-Ventricular Assist Device (LVAD) Implantation as Destination Therapy (DT) 2006
  • Sudden Cardiac Death in Patients with Diastolic Heart Failure 2006
  • The ESCAPE Discharge Risk Score: Don't Go Home without It 2006
  • Effect of eplerenone in a high risk subgroup with low blood pressure and elevated heart rate: Results from the EPHESUS trial 2005
  • Evolution of hemoglobin concentration in outpatients with heart failure: Results from the study of anemia in a heart failure population (STAMINA-HFP) registry 2005
  • Relation between diuretic dose and outcome in a heart failure population: Results of the ESCAPE trial 2005
  • The effect of valsartan, captopril, or both on atherosclerotic events after myocardial infarction: An analysis of the VALIANT trial 2005
  • A Multidisciplinary Cardiac Rehabilitation Program Dramatically Improves Long-Term Morbidity and Mortality Following Congestive Heart Failure Admission 2004
  • Adverse Impact of Diastolic Heart Failure on Exercise Tolerance 2004
  • Anemia and survival in patients with heart failure and preserved systolic function 2004
  • Anemia, coronary artery disease severity, and survival in chronic heart failure 2004
  • Lower Hemoglobin Is Associated with Persistently Reduced Quality of Life in Unselected Patients with Heart Failure: Results from the Study of Anemia in a Heart Failure Population (STAMINA-HFP) Registry 2004
  • Reduction in all-cause mortality and morbidity with candesartan in patients with chronic heart failure and systolic left ventricular dysfunction: results of the CHARM low EF trials 2004